These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14650931)

  • 21. Taking the pulse of strategic outsourcing relationships.
    Getz KA; Lamberti MJ; Kaitin KI
    Clin Ther; 2014 Oct; 36(10):1349-55. PubMed ID: 25444564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can China bring its own pipeline to the market?
    Louët S
    Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
    [No Abstract]   [Full Text] [Related]  

  • 24. The promise of the East: India and China as R&D options.
    Goodall S; Janssens B; Wagner K; Wong J; Woods W; Yeh M
    Nat Biotechnol; 2006 Sep; 24(9):1061-4. PubMed ID: 17061321
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative assessment for medications and devices: apples and oranges?
    Ramsey S
    Value Health; 2010 Jun; 13 Suppl 1():S12-4. PubMed ID: 20618788
    [No Abstract]   [Full Text] [Related]  

  • 26. McClellan's FDA: boon to industry, consumers, or both? New FDA chief plans to speed drug approval and reduce costs.
    Ault A
    Lancet; 2003 Aug; 362(9381):379-80. PubMed ID: 12911016
    [No Abstract]   [Full Text] [Related]  

  • 27. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging trends in contract research industry in India.
    Drabu S; Gupta A; Bhadauria A
    Contemp Clin Trials; 2010 Sep; 31(5):419-22. PubMed ID: 20609394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 31. Contract research organizations (CROs) may be the next trend in clinical trials liability.
    Valdes S; McGuire P
    J Biolaw Bus; 2004; 7(3):11-5. PubMed ID: 15460602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing conflicts of interest: a survival guide for biotechs.
    Werner MJ; Price E
    Nat Biotechnol; 2007 Feb; 25(2):161-3. PubMed ID: 17375384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical devices on trial, Part I.
    Wright D
    Med Device Technol; 2002 Dec; 13(10):35-8. PubMed ID: 12575529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncology drug development: United States Food and Drug Administration perspective.
    Hirschfeld S; Pazdur R
    Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Missing evidence.
    Hayes WS
    MLO Med Lab Obs; 2008 Oct; 40(10):68. PubMed ID: 18988559
    [No Abstract]   [Full Text] [Related]  

  • 36. Demystifying the U.S. Food and Drug Administration: understanding regulatory pathways.
    Naghshineh N; Brown S; Cederna PS; Levi B; Lisiecki J; D'Amico RA; Hume KM; Seward W; Rubin JP
    Plast Reconstr Surg; 2014 Sep; 134(3):559-569. PubMed ID: 25158712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 38. The 21st Century Cures Act: can the regulatory framework survive the "cures"?
    Osorio-de-Castro CG; Caetano R; Pepe VL
    Cad Saude Publica; 2015 Sep; 31(9):1807-10. PubMed ID: 26578005
    [No Abstract]   [Full Text] [Related]  

  • 39. Bilski blundering biotech.
    Simmons WJ
    Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
    [No Abstract]   [Full Text] [Related]  

  • 40. Integration of new technology into clinical practice after FDA approval.
    Govil A; Hao SC
    J Interv Card Electrophysiol; 2016 Oct; 47(1):19-27. PubMed ID: 27565971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.